Merck KGaA, the chemicals and pharmaceuticals group, posted 1Q net income surged to 458 million euros from 190 million euros in the prior-year period and adjusted EBITDA rose 27.2% on year to 1.18 billion euros on revenue of 4.37 billion euros, up 16.7%. Regarding full-year outlook, the company said: "Group EBITDA pre is expected to be in a range of between E4.35 billion and E4.85 billion. Owing to strong restrictions of economic life and declining income in the context of the Covid-19 pandemic with correspondingly adverse effects on the businesses, Merck forecasts a merely stable organic development."
From a technical perspective, the bearish gap opened this morning calls for a short term consolidation move. However, the trend remains bullish. A pennant pattern is taking shape. (Continuation trend pattern). The daily Relative Strength Index (RSI, 14) is above 50% and is not overbought (<70%).
As long as 95E is support, the bias is bullish. The validation of the pennant pattern would call for a new rise towards 110E and 118.4E.
Alternatively, a break below 95E would negate the bullish view and would call for a reversal down trend with 87.45E as first target.
Source: GAIN Capital, TradingView